A phase 2, randomized, double-blind, placebo-controlled, flexible escalating -dose, pilot analgesic efficacy study of T-62 in subjects with postherpetic neuralgia
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2012
At a glance
- Drugs T 62 (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- 13 May 2012 Company (Pfizer) added to the associations field as reported by ClinicalTrials.gov record.
- 13 Nov 2007 Status changed from recruiting to withdrawn prior to recruitment.
- 20 Aug 2007 New trial record.